Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

University only

What are the characteristics of HIV transmission that allow us to optimise prevention? How do they vary by setting and over time? The PANGEA-HIV consortium -- described here -- was set up to investigate this using HIV virus genomics, epidemiology and behavioural science. >90% of virus genomes available from Southern and Eastern Africa were generated by PANGEA, working in underserved populations with very high HIV infection rates. The consortium brings together experts in six leading African centres working alongside epidemiologists, behavioural scientists and ethicists in the UK and USA. We are generating evidence that shapes HIV prevention programmes. I will describe multidisciplinary investigations and trials that assess the increasing impact that treatment has in preventing transmission. Antiretroviral therapy has been the cornerstone, but other factors influence. Progress has been fast enough that UNAIDS has declared that on current pace, 'AIDS will end as a public health threat' by 2030. Several countries have already met the goals set for 2030. And yet, treatment will be needed for decades, and many new infections will arise. I will describe what we are learning about the changing patterns of infection and prevention, looking towards 2030 and beyond.

Forthcoming events

Richard Doll Seminar - Adventures in Digital Health Research: Alcohol, Coffee, and Arrhythmias

Tuesday, 03 September 2024, 1pm to 2pm @ Richard Doll Lecture Theatre, Richard Doll Building, OldRoad Campus, University of Oxford, OX3 7LF